Evidence map›Paper›PMID 39062189›Full record

ArticleBiomedicines2024

Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia.

Danaë Martinez Flores, Dilara Akhoundova, Katja Seipel, Myriam Legros, Marie-Noelle Kronig, Michael Daskalakis, Ulrike Bacher, Thomas Pabst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Danaë Martinez FloresDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Berne, Switzerland.
Dilara AkhoundovaDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Berne, Switzerland.ORCID 0000-0003-1639-3059
Katja SeipelDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Berne, Switzerland.ORCID 0000-0003-3128-1573
Myriam LegrosDepartment of Clinical Chemistry and Center for Laboratory Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Berne, Switzerland.
Marie-Noelle KronigDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Berne, Switzerland.
Michael DaskalakisDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Berne, Switzerland.ORCID 0000-0002-8138-0505
Ulrike BacherDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Berne, Switzerland.ORCID 0000-0001-8771-947X
Thomas PabstDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Berne, Switzerland.ORCID 0000-0002-6055-5257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemtuzumab ozogamicin (GO), a CD33-targeting antibody drug conjugate, previously showed longer relapse-free survival when combined with induction chemotherapy in patients with favorable-risk acute myeloid leukemia (AML). In this patient population, characterized by lower relapse risk as compared to other ELN risk groups, autologous stem cell transplantation (ASCT) can be used as consolidation strategy. However, there are limited data on the impact of GO on the peripheral blood stem cell (PBSC) mobilization potential. We therefore retrospectively analyzed data from 54 AML patients with favorable-risk AML treated with (

Indexed as

acute myeloid leukemia (AML)autologous stem cell transplantation (ASCT)gemtuzumab ozogamicin (GO)peripheral blood stem cells (PBSC)stem cell mobilization

Identifiers

PMID39062189
PMCPMC11274629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.